Sharemaestro company-news research for Parabilis Medicines, Inc. Common Stock (PBLS), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

PBLS news sentiment

Parabilis Medicines, Inc. Common Stock

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score51Neutral is 50
Early balanced news score 18/100 evidence confidence 100% direct company focus 24 current stories across 2 publishers
Latest weekly closeUSD 39.36week of 21 Aug 2026
Main news subjectMarket update78/100 share of current news
News data statusHealthy28 duplicate stories removed

Current company news

Early balanced news score

24 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone66/100 Published 30-day score51/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Parabilis Medicines Shares Expected to Start Trading on Nasdaq Global Select Market on June 10 Under Ticker 'PBLS' Moomoo ยท 20 Aug 2026 00:41

What supports the score

Direct evidence

24 current stories are mapped specifically to PBLS.

What limits the score

Source breadth

Only 2 publishers currently contribute to the measured read.

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.039.

Confidence

Confidence is 18/100, below the threshold for a firm score.

51/100
News scoreEarly balanced news score
18/100
Confidencethin evidence
100%/100
Company news24 company stories
100/100
Story agreement0/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
27 Jul: 1 stories31 Jul: 1 stories02 Aug: 2 stories06 Aug: 2 stories08 Aug: 1 stories10 Aug: 1 stories13 Aug: 5 stories14 Aug: 4 stories15 Aug: 2 stories17 Aug: 1 stories18 Aug: 2 stories19 Aug: 1 stories20 Aug: 1 stories 27 Jul: tone 50, 1 stories31 Jul: tone 60, 1 stories02 Aug: tone 50, 2 stories06 Aug: tone 50, 2 stories08 Aug: tone 50, 1 stories10 Aug: tone 56, 1 stories13 Aug: tone 57, 5 stories14 Aug: tone 50, 4 stories15 Aug: tone 50, 2 stories17 Aug: tone 50, 1 stories18 Aug: tone 50, 2 stories19 Aug: tone 50, 1 stories20 Aug: tone 50, 1 stories 95505
27 Jul11 Aug25 Aug
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence1
0.039 after freshness weighting
Source breadth40
2 independent publishers
Company relevance100
share tied directly to this company
Freshness14
recency-weighted evidence
Agreement100
how closely stories agree
Publisher mix0
less reliance on one publisher

Price and news history

News score and weekly price over 26 weeks

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
12 Jun 2026: close 27.26, indexed 100.019 Jun 2026: close 25.85, indexed 94.826 Jun 2026: close 28.8, indexed 105.603 Jul 2026: close 29.58, indexed 108.510 Jul 2026: close 30.57, indexed 112.117 Jul 2026: close 29.55, indexed 108.424 Jul 2026: close 31.28, indexed 114.731 Jul 2026: close 33.98, indexed 124.707 Aug 2026: close 34.98, indexed 128.314 Aug 2026: close 37.07, indexed 136.021 Aug 2026: close 39.36, indexed 144.4 12 Jun 2026: news score 50, close 27.26, 3 stories5019 Jun 2026: news score 50, close 25.85, 6 stories26 Jun 2026: news score 50, close 28.8, 6 stories5003 Jul 2026: news score 50, close 29.58, 6 stories10 Jul 2026: news score 51, close 30.57, 10 stories5117 Jul 2026: news score 50, close 29.55, 5 stories24 Jul 2026: news score 50, close 31.28, 4 stories5031 Jul 2026: news score 51, close 33.98, 7 stories07 Aug 2026: news score 50, close 34.98, 8 stories5014 Aug 2026: news score 52, close 37.07, 16 stories21 Aug 2026: news score 51, close 39.36, 23 stories51
12 Jun17 Jul21 Aug
Weekly close, indexedSentiment score
26-week price+44.4%latest close 39.36
News score change+1first to latest comparable week
One-week response+6.2%Price confirming higher
Fair-value position+24.3%Near fair-value range
WeekNews scoreCloseWeekly move
21 Aug 202651USD 39.36+6.2%
14 Aug 202652USD 37.07+6.0%
07 Aug 202650USD 34.98+2.9%
31 Jul 202651USD 33.98+8.6%
24 Jul 202650USD 31.28+5.9%
17 Jul 202650USD 29.55-3.3%
10 Jul 202651USD 30.57+3.3%
03 Jul 202650USD 29.58+2.7%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update5012 stories ยท 50%
Earnings5410 stories ยท 42%
Deals and strategy501 stories ยท 4%
Balance sheet501 stories ยท 4%

Source mix

Where the evidence comes from

0/100 independence
MarketBeat506 stories ยท 25%
Stock Titan504 stories ยท 17%
marketscreener.com602 stories ยท 8%
Moomoo502 stories ยท 8%
TradingKey601 stories ยท 4%
Simply Wall Street561 stories ยท 4%
StocksToTrade501 stories ยท 4%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences9Financial Markets7Finance6Earnings6IPO5Financial Results1Economy Macro1Clinical Trials1Biotech1Balance Sheet1

Earlier readings

How the score has changed

21 comparable readings ยท 73 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+050 to 50 ยท Broadly stable
Observed range50โ€“5350 is the neutral baseline
Evidence depth22stories at latest stored reading ยท +19
Confidence18/100Provisional ยท +18
12 Jun50 neutral25 Aug 08:30
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
25 Aug 08:3050-118/100 (-2)22 (-1)Provisional
20 Aug 23:5951+020/100 (-1)23 (+1)Provisional
19 Aug 23:5951+021/100 (-1)22 (+1)Provisional
18 Aug 23:5951+022/100 (-1)21 (+2)Provisional
17 Aug 23:5951-123/100 (-3)19 (+1)Provisional
15 Aug 23:5952+026/100 (-2)18 (+2)Provisional
14 Aug 23:5952+028/100 (-2)16 (+2)Provisional
13 Aug 23:5952+230/100 (+15)14 (+6)Provisional

Source headlines

The news behind the score

Showing 1-24 of 24

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
MoomooDirect company coverageStored article

Parabilis Medicines Shares Expected to Start Trading on Nasdaq Global Select Market on June 10 Under Ticker 'PBLS'

Parabilis Medicines announced that its shares are anticipated to begin trading on the Nasdaq Global Select Market on June 10. The company will use the ticker symbol 'PBLS'. This move marks a significant step for Parabilis Medicines in its public market presence.

Financial MarketsIPOLife Sciences
Published
20 Aug 2026 00:41
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 5.3d old
Duplicates
1 consolidated
#2—Not directional
MarketBeatDirect company coverageScored from headline

Top Parabilis Medicines (PBLS) Competitors 2026

Published
19 Aug 2026 17:06
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 5.6d old
Duplicates
1 consolidated
#3—Not directional
MarketBeatDirect company coverageScored from headline

Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9% - Here's What Happened

Published
18 Aug 2026 19:26
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 6.5d old
Duplicates
1 consolidated
#4—Not directional
MarketBeatDirect company coverageScored from headline

Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS

Published
18 Aug 2026 08:06
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 7.0d old
Duplicates
1 consolidated
#5—Not directional
MarketBeatDirect company coverageScored from headline

Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year High - What's Next?

Published
17 Aug 2026 13:43
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 7.8d old
Duplicates
1 consolidated
#6—Not directional
MoomooDirect company coverageStored article

Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News

The article provides information related to Parabilis Medicines (PBLS) stock options chain, including quotes and news. The content itself is not available in the provided input.

FinanceFinancial Markets
Published
15 Aug 2026 05:12
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 10.1d old
Duplicates
1 consolidated
#7—Not directional
StocksToTradeDirect company coverageScored from headline

Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ

Published
15 Aug 2026 00:34
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 10.3d old
Duplicates
1 consolidated
#8—Not directional
Stock TitanDirect company coverageStored article

Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership

ARCH Venture Fund XII and related entities have disclosed a 5.3% beneficial ownership stake in Parabilis Medicines (PBLS), amounting to 6,412,780 shares of common stock. This Schedule 13G filing indicates a passive investment, with ARCH Venture Partners XII, L.P., ARCH Venture Partners XII, LLC, and four committee members sharing voting and dispositive power over these shares. The ownership percentage is based on 121,952,030 shares outstanding as of August 10, 2026.

FinanceLife Sciences
Published
14 Aug 2026 20:10
News subject
Deals and strategy
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 10.5d old
Duplicates
2 consolidated
#9—Not directional
Stock TitanDirect company coverageStored article

Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal

Parabilis Medicines, Inc. reported its Q2 2026 results, showing a significant increase in cash and cash equivalents to over $1.1 billion. This boost follows its June 2026 IPO, which generated $787.9 million in net proceeds, and a $50.0 million upfront payment from its collaboration agreement with Regeneron. The company, a clinical-stage biopharmaceutical firm, is focused on developing Helicon peptide therapeutics and reported a net loss of $97.8 million for the six months ended June 30, 2026.

EarningsEconomy MacroFinanceIPOLife Sciences
Published
14 Aug 2026 05:12
News subject
Earnings
Why this score
Negative financial language
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 11.1d old
Duplicates
2 consolidated
#10—Not directional
marketscreener.comDirect company coverageStored article

Earnings Flash (PBLS) Parabilis Medicines, Inc. Reports Q2 Revenue $148,000

Parabilis Medicines, Inc. (PBLS) reported its Q2 revenue as $148,000. The company, a clinical-stage biopharmaceutical firm, focuses on developing transformative medicines for "undruggable" protein targets using its proprietary Helicon platform. Analysts currently have a "BUY" consensus for PBLS with an average target price of $41.75, representing a potential upside of 12.62% from its last close price of $37.07.

EarningsFinancial MarketsIPOLife Sciences
Published
14 Aug 2026 02:10
News subject
Earnings
Why this score
Positive financial language
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 11.3d old
Duplicates
1 consolidated
#11—Not directional
Investing.com NigeriaDirect company coverageStored article

Form 8K Parabilis Medicines For: 13 August By Investing.com

The article is a brief financial news item from Investing.com, reporting on a Form 8K filing by Parabilis Medicines for August 13th. It provides no further details beyond stating the filing occurred on that date.

FinanceLife Sciences
Published
14 Aug 2026 02:10
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 11.3d old
Duplicates
1 consolidated
#12—Not directional
KING5.comDirect company coverageScored from headline

Parabilis Medicines: Q2 Earnings Snapshot

Published
13 Aug 2026 11:07
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 11.9d old
Duplicates
1 consolidated
#13—Not directional
Stock TitanDirect company coverageScored from headline

PARABILIS MEDICINES (PBLS) Stock News & Updates

Published
13 Aug 2026 11:00
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 11.9d old
Duplicates
1 consolidated
#1466Tone
marketscreener.comDirect company coverageStored article

Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell

Parabilis Medicines reported a narrower Q2 net loss of $2.32 per share, with revenue reaching $148,000. Following this news, the company's shares experienced a rise in pre-bell trading. Parabilis Medicines, formerly FOG Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on developing transformative medicines for undruggable protein targets using its proprietary Helicons platform.

EarningsFinancial MarketsLife Sciences
Published
13 Aug 2026 11:40
News subject
Earnings
Why this score
Loss narrowed
Company focus
Main company ยท 100%
How it is used
Direct company coverage
Story strength
Medium ยท 48/100
30-day weight
100% of the score ยท 11.9d old
Duplicates
1 consolidated
#15—Not directional
GlobeNewswireDirect company coverageStored article

Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates

Parabilis Medicines reported its second quarter 2026 financial results, highlighting significant progress in advancing zolucatetide for Wnt/ฮฒ-catenin-driven diseases and expanding its Heliconโ„ข platform through a collaboration with Regeneron. The company ended the quarter with a strong financial position of $1.1 billion in cash, cash equivalents, and marketable securities, projected to fund operations into 2030, following a successful $770.5 million initial public offering. Key milestones include planned Phase 3 development for desmoid tumors and upcoming clinical data presentations for various indications.

Balance SheetBiotechClinical TrialsEarningsFinanceFinancial Results
Published
13 Aug 2026 10:40
News subject
Earnings
Why this score
Positive financial language
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 11.9d old
Duplicates
3 consolidated
#16—Not directional
MarketBeatDirect company coverageScored from headline

Parabilis Medicines (PBLS) Earnings Date and Reports 2026

Published
13 Aug 2026 07:00
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 12.1d old
Duplicates
1 consolidated
#17—Not directional
Simply Wall StreetDirect company coverageStored article

Parabilis Medicines (Nasdaq:PBLS) - Stock Analysis

Parabilis Medicines (PBLS) is a clinical-stage biopharmaceutical company with a market cap of US$4.6 billion. The company recently completed a record-breaking biotech IPO, raising substantial capital to fund a pivotal Phase 3 cancer therapy trial and expand its Helicon platform. Despite significant capital raises and investor interest, the stock has experienced choppy trading since its debut.

EarningsFinancial MarketsIPOLife Sciences
Published
10 Aug 2026 09:11
News subject
Earnings
Why this score
Business expansion
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 15.0d old
Duplicates
1 consolidated
#18—Not directional
The Chronicle-JournalDirect company coverageStored article

Parabilis Medicines, Inc. - Common Stock (Nasdaq:PBLS) Stock Quote

This article provides a stock quote and related news for Parabilis Medicines, Inc. (PBLS). It includes current trading information, performance data, and recent news headlines highlighting the company's IPO success and insider stock purchases, indicating significant interest and investment in the biotech firm.

Financial MarketsIPOLife Sciences
Published
08 Aug 2026 09:39
News subject
Market update
Why this score
Institutional or insider buying
Company focus
Shared story ยท 78%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 17.0d old
Duplicates
1 consolidated
#19—Not directional
Stock TitanDirect company coverageStored article

FMR LLC reports 10.3M-share position in Parabilis Medicines Inc (PBLS)

FMR LLC has filed a Schedule 13G, disclosing a passive ownership stake of 10,292,735 shares, representing 8.5% of Parabilis Medicines Inc.'s outstanding common stock. Both FMR LLC and Abigail P. Johnson, a reporting person, hold sole dispositive power over these shares, with FMR LLC also holding sole voting power. The filing emphasizes transparency regarding significant ownership and its potential impact on corporate governance.

EarningsFinanceFinancial MarketsLife Sciences
Published
06 Aug 2026 16:09
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 18.7d old
Duplicates
2 consolidated
#20—Not directional
Market sourceDirect company coverageScored from headlineSource lookup

Tenet Healthcare (THC) Stock Still Looks Cheap On Earnings

Published
06 Aug 2026 09:59
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 18.9d old
Duplicates
1 consolidated
#21—Not directional
Zacks Investment ResearchDirect company coverageScored from headlineSource lookup

Parabilis Medicines, Inc. (PBLS) Cash Equivalents (Quarterly)

Published
02 Aug 2026 18:03
News subject
Balance sheet
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 22.6d old
Duplicates
1 consolidated
#22—Not directional
MarketBeatDirect company coverageScored from headlineSource lookup

Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Buy" by Analysts

Published
02 Aug 2026 05:19
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 23.1d old
Duplicates
1 consolidated
#2360Tone
TradingKeyDirect company coverageScored from headlineSource lookup

PBLS|Parabilis Medicines Ord Shs|Price:32.125|Chg%:+0.165

Published
31 Jul 2026 09:51
News subject
Market update
Why this score
Positive market reaction
Company focus
Main company ยท 100%
How it is used
Direct company coverage
Story strength
Low ยท 33/100
30-day weight
<0.1% of the score ยท 24.9d old
Duplicates
1 consolidated
#24—Not directional
AD HOC NEWSDirect company coverageScored from headlineSource lookup

Johnson & Johnson stock trades steadily as diversified healthcare earnings support valuation

Published
27 Jul 2026 04:10
News subject
Earnings
Why this score
The headline reports news without a clear direction
Company focus
Main company ยท 100%
How it is used
Shown as company news ยท not used in the score
Story strength
Not directional
30-day weight
None ยท 29.2d old
Duplicates
1 consolidated

Earlier company news

PBLS news archive

11 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 11 older PBLS headlines. Open one page at a time when you need them.

Open older archive

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context